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Articles
Eﬀ ects of naloxone distribution alone or in combination 
with addiction treatment with or without pre-exposure 
prophylaxis for HIV prevention in people who inject drugs: 
a cost-eﬀ ectiveness modelling study
Jennifer Uyei, David A Fiellin, Marianne Buchelli, Ramon Rodriguez-Santana, R Scott Braithwaite
Summary
Background In the USA, an epidemic of opioid overdose deaths is occurring, many of which are from heroin. 
Combining naloxone distribution with linkage to addiction treatment or pre-exposure prophylaxis (PrEP) for HIV 
prevention through syringe service programmes has the potential to save lives and be cost-eﬀ ective. We estimated the 
outcomes and cost-eﬀ ectiveness of ﬁ ve alternative strategies: no additional intervention, naloxone distribution, 
naloxone distribution plus linkage to addiction treatment, naloxone distribution plus PrEP, and naloxone distribution 
plus linkage to addiction treatment and PrEP.
Methods We developed a decision analytical Markov model to simulate opioid overdose, HIV incidence, overdose-
related deaths, and HIV-related deaths in people who inject drugs in Connecticut, USA. Model input parameters were 
derived from published sources. We compared each strategy with no intervention, as well as simultaneously 
considering all strategies. Sensitivity analysis was done for all variables. Linkage to addiction treatment was referral to 
an opioid treatment programme for methadone. Endpoints were survival, life expectancy, quality-adjusted life-years 
(QALYs), number and percentage of overdose deaths averted, number of HIV-related deaths averted, total costs (in 
2015 US$) associated with each strategy, and incremental cost per QALY gained.
Findings In the base-case analysis, compared with no additional intervention, the naloxone distribution strategy 
yielded an incremental cost-eﬀ ectiveness ratio (ICER) of $323 per QALY, and naloxone distribution plus linkage to 
addiction treatment was cost saving compared with no additional intervention (greater eﬀ ectiveness and less 
expensive). The most eﬃ  cient strategies (ie, those conferring the greatest health beneﬁ t for a particular budget) were 
naloxone distribution combined with linkage to addiction treatment (cost saving), and naloxone distribution combined 
with PrEP and linkage to addiction treatment (ICER $95 337 per QALY) at a willingness-to-pay threshold of $100 000. 
In probabilistic sensitivity analysis, the combination of naloxone distribution, PrEP, and linkage to addiction 
treatment was the optimal strategy in 37% of iterations and the combination of naloxone distribution and linkage to 
addiction treatment was the optimal strategy in 34% of iterations.
Interpretation Naloxone distribution through syringe service programmes is cost-eﬀ ective compared with syringe 
distribution alone, but when combined with linkage to addiction treatment is cost saving compared with no additional 
services. A strategy that combines naloxone distribution, PrEP, and linkage to addiction treatment results in greater 
health beneﬁ ts in people who inject drugs and is also cost-eﬀ ective.
Funding State of Connecticut Department of Public Health.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
license. 
Introduction
In the USA, an epidemic of drug overdose deaths is 
occurring; most of these deaths (61%) involve some type of 
opioid.1 The surge in overdose deaths from heroin in recent 
years (tripling from 2010 to 2014) contributes to nearly half 
of all opioid deaths (following natural and semisynthetic 
opioids such as morphine, oxycodone, and hydrocodone).1 
33 US states have syringe service programmes in roughly 
200 cities,2 which in some areas serve as a venue for 
community distribution of naloxone. Naloxone is an opioid 
antagonist that reverses the potentially fatal respiratory or 
central nervous system depression caused by opioid 
overdose.3 Community-based opioid overdose prevention 
programmes that include the distribution of naloxone to 
non-medical bystanders have been shown to improve the 
ability of bystanders to recognise and eﬀ ectively respond to 
an overdose4 and to reduce opioid overdose deaths.4–8 A 
recent economic analysis showed that such programmes 
are cost-eﬀ ective (US$438 per quality-adjusted life-year 
[QALY] gained) when targeted at people who use heroin, 
even after taking into consideration the likely continued 
use of heroin after surviving an overdose.9
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Although community-based naloxone distribution is 
clearly beneﬁ cial and cost-eﬀ ective, a more compre-
hensive strategy to maximise the health of people who 
inject drugs is likely to require additional components 
that aim to address the underlying substance use 
disorder10,11 or reduce transmission of HIV and hepatitis C 
virus (HCV). We assess the eﬀ ects of combining naloxone 
distribution with linkage to addiction treatment, with or 
without pre-exposure prophylaxis (PrEP) for HIV 
prevention. Addiction treatment for people who inject 
drugs has been shown to substantially improve the 
health of not only people who inject drugs, but also the 
general population because of the reduction in HIV 
infections. This strategy is also cost-eﬀ ective, with one 
economic study reporting a cost per additional QALY of 
$11 923 (US$ 2015).12 PrEP has been shown to 
substantially reduce the probability of HIV infection in 
people who inject drugs, but the value of expanding PrEP 
is variable, with the cost per QALY gained in the range of 
$50 000–350 000, and sensitive to HIV prevalence and 
the cost of PrEP.13,14
Mathematical models are important to inform policy 
and decision making because it is diﬃ  cult to tell whether 
the advantages of combination strategies will be 
attenuated when considering the downstream costs 
associated with treating substance use disorders, HIV, 
hepatitis C, and their sequelae, or ampliﬁ ed because of 
the cases of HIV and hepatitis C that are averted. We 
investigated the health beneﬁ t and cost-eﬀ ectiveness of 
the current naloxone distribution programme in 
Connecticut, USA, as well as three novel combination 
strategies that combine naloxone distribution with 
linkage to addiction treatment with or without PrEP.
Methods
Description of strategies
We compared ﬁ ve strategies: (1) no additional inter-
vention, (2) naloxone distribution, (3) naloxone 
distribution plus linkage to addiction treatment, 
(4) naloxone distribution plus PrEP, and (5) naloxone 
distribution plus linkage to addiction treatment and 
PrEP. The no additional intervention strategy served as a 
comparator and assumed a scenario in which none of 
the other four strategies were added to syringe exchange. 
The naloxone distribution strategy reﬂ ects the current 
strategy in Connecticut in which overdose kits consisting 
of two preﬁ lled syringes of naloxone, atomisers for 
intranasal administration, gloves, alcohol pad, rescue 
breathing mask, and written instructions are distributed 
via mobile syringe service programmes, AIDS service 
organisations, and other community-based organ-
isations. Naloxone distribution plus linkage to addiction 
treatment is an untested strategy (but based on 
established programmes15–18), in which referral to 
methadone treatment is added to existing naloxone 
programmes and operates concurrently. The naloxone 
distribution plus PrEP strategy, in which PrEP is added 
to the existing naloxone programme, is also untested. 
The ﬁ nal strategy combines all of the strategies 
described.
Research in context
Evidence before this study
Evidence suggests that community-based naloxone 
distribution improves the ability of bystanders to recognise 
and effectively respond to an opioid overdose and is 
cost-effective. However, a more comprehensive strategy to 
maximise the health of people who inject drugs is likely to 
require additional services that aim to address the underlying 
substance use disorder or reduce transmission of HIV and 
hepatitis C virus (HCV). Such services include linkage to 
addiction treatment and pre-exposure prophylaxis (PrEP) for 
HIV prevention. We searched PubMed on Dec 21, 2015, and 
again on June 15, 2016, with the search terms Naloxone AND 
(PrEP or pre-exposure prophylaxis) Naloxone AND (“drug 
treatment” OR “addiction treatment” OR methadone), 
without any restrictions for date of publication or 
geographical location. We also searched bibliographies of 
relevant articles. Although combination strategies are not 
new, we did not identify any published research that reported 
their effectiveness, feasibility, or value.
Added value of this study
Mathematical models are important to inform policy and 
decision making to ascertain whether the possible advantages of 
combination strategies will be attenuated when considering the 
downstream costs associated with treating substance use 
disorders, HIV, hepatitis C, and their sequelae, or ampliﬁ ed 
because of the cases of HIV and hepatitis C that are averted. In 
this study, we investigated the eﬀ ects of naloxone distribution 
alone or in combination with addiction treatment with or 
without PrEP. We did not explicitly model HCV or its treatment.
Implications of all the available evidence
Our analyses suggest that naloxone distribution through syringe 
service programmes is cost-eﬀ ective compared with no 
additional intervention. The addition of linkage to addiction 
treatment is cost saving compared with either no additional 
intervention or naloxone distribution alone. Combining PrEP 
with naloxone distribution and linkage to addiction treatment 
resulted in the greatest health gains and is cost-eﬀ ective, with an 
ICER of less than US$100 000 per quality-adjusted life-year 
gained. 
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Opioid overdose Markov model
The research questions, model structure, and parameters 
were developed and selected in consultation with 
programme implementation and policy experts at the 
Connecticut Department of Public Health and discussed 
with other experts in the ﬁ eld of addiction and HIV 
infection who are knowledgeable about service delivery 
for individuals in Connecticut who use drugs. We 
developed a decision analytical Markov model (appendix) 
to simulate opioid overdose in HIV-negative people who 
inject drugs in Connecticut to estimate the short-term 
(5 years) and long-term (time horizon of 5, 10, and 
20 years) survival, life expectancy, QALY, number and 
percentage of overdose deaths averted, number of HIV-
related deaths averted, total costs associated with each 
strategy, and incremental cost-eﬀ ectiveness ratio (ICER). 
For all strategies, we assumed that in each year 30% of 
the cohort received the services oﬀ ered in that strategy, 
with the exception of strategies that included linkage to 
addiction treatment, in which 6% entered methadone 
treatment. For example, in the strategy that consisted of 
naloxone distribution, linkage to addiction treatment, 
and PrEP, 30% of participants received naloxone, 6% 
entered methadone treatment, and 30% started PrEP. 
We took a more conservative approach in selecting the 
6% estimate and tested a less restrictive range (up to 96% 
annual enrolment) in sensitivity analysis. Because 
enrolment or re-enrolment into addiction treatment can 
occur without exposure to active engagement, we 
included a baseline annual probability of 4% enrolment. 
The initial cohort consisted of 5400 HIV-negative people 
who inject drugs who were not on PrEP. Because we did 
not ﬁ nd published estimates speciﬁ cally for Connecticut, 
we estimated this value by applying the proportion of 
current heroin users in the USA in 2014 (0·2%)19 to the 
population of Connecticut aged 15 years and older 
(2 967 252), and then subtracted out the number of HIV-
infected people who inject drugs based on prevalence 
estimates (9%).20 Discontinuation of injecting behaviour 
was inﬂ uenced by entering addiction treat ment, addiction 
treatment eﬃ  cacy (25% annual discon tinuation if 
enrolled in addiction treatment), a non-fatal overdose 
episode (6% per episode), and relapse to injection drug 
use (7% per year). Because we found no empirical studies 
reporting the likelihood of discon tinuing injection drug 
use after an overdose, we followed the assumptions 
reported by Coﬃ  n and colleagues9 and used a 6% 
probability per episode. Because rates in the model were 
constant over time, we chose a lower rate of relapse to 
injection drug use to avoid overestimation over a 20-year 
time horizon and, in sensitivity analysis, tested higher 
values up to 85%, which many experts have observed in 
practice. In view of the gap in the current understanding 
of PrEP adherence in people who inject drugs,21 we 
assumed an annual rate that was similar for antiretroviral 
therapy for this same population (adherence probability 
of 41%). PrEP adherence aﬀ ects the eﬃ  cacy of PrEP and 
thereby aﬀ ects transmission probability of HIV. This 
assumption may or may not reﬂ ect reality and thus wide 
margins were tested in sensitivity analysis. HIV infection 
was informed by injecting status and PrEP use, and once 
HIV-positive the likelihood of detection was 50%, a 
function of the rate of HIV testing and test sensitivity. 
Among individuals with detected HIV infection, we 
assumed that HIV antiretroviral therapy was initiated and 
41%22 achieved acceptable adherence, of whom 55%23 
achieved viral suppression. Rates for discontinuing 
injecting behaviour and entering addiction treatment 
were unaﬀ ected by HIV status. Excess mortality was 
lower in individuals who achieved HIV viral suppression 
(0·003) compared with those who did not (0·02).
We deﬁ ned overdose as the rapid onset of loss of 
consciousness (accompanied by minimal responsiveness) 
from which arousal was diﬃ  cult or impossible.24,25 
Overdose and overdose-related death was modelled 
through a series of probabilistic events that could occur 
in each cycle. We assumed the likelihood of an overdose 
per year was 7·7%, with an 85% chance the overdose was 
witnessed, a 39% chance that naloxone was administered 
if the bystander had a naloxone kit, and a 97% likelihood 
of survival if the kit was used. If no kit was used and 
paramedics were not dispatched, survival was 86%. On 
the basis of ﬁ ndings from several studies4,26,27 showing 
that the likelihood of calling paramedics was reduced if 
naloxone was administered, we assumed a 69% reduction 
in the likelihood of paramedics being dispatched in such 
cases. Mortality was based on overdose survival, HIV 
status, and background age and sex speciﬁ c mortality 
rates reported in US life tables.28 Model validation is 
discussed in the appendix. The model was developed in 
Excel 2013 and all analyses were done in Excel.
Model parameters, costs, and utilities
Model input parameters were derived from published 
sources (appendix). The cost of the naloxone kit reﬂ ects the 
current price that the Connecticut Department of Public 
Health pays per dose of naloxone ($33 × 2 doses=$66) plus 
costs associated with distribution ($10 per recipient). 
Paramedic dispatch cost ($3182) included basic life support 
response, transport to the emergency department, and an 
assessment. Admission to hospital after an assessment, 
which occurred in 11% of dispatch cases, cost $15 845. The 
annual cost of PrEP per person ($11 800) included the cost 
of medication, four doctor visits, and laboratory tests. The 
annual cost of HIV antiretroviral treatment per patient 
($32 652) was taken from a recent study29 in which the 
costs of medication and care for HIV-positive people who 
inject drugs were estimated by use of data from a 
consortium of hospital and community-based HIV care 
sites in the USA. The annual cost of methadone treatment 
per person was $4821, which is based on ﬁ ndings from a 
study30 that estimated costs for 25 methadone treatment 
programmes in 12 states in the USA and included in its 
estimate the cost of personnel and direct and indirect costs 
See Online for appendix
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for patient assessment, medical services, individual and 
group counselling, methadone, patient education, and 
case management. All costs were converted into 2015 US$ 
and discounted at an annual rate of 3%.31
Base case and sensitivity analysis
For each intervention strategy, we projected survival 
probability, life expectancy, QALY, and cost, and then 
compared projections to the no additional intervention 
strategy to estimate health eﬀ ects. To identify the most 
eﬃ  cient strategies, ICERs for each strategy were compared 
for a time horizon of 20 years. Ineﬃ  cient strategies were 
disqualiﬁ ed from consideration on the basis of strong and 
weak dominance. A cost-eﬀ ectiveness threshold of $100 000 
per QALY was used, which approximates the cost-
eﬀ ectiveness of the US health system in the aggregate, and 
therefore reﬂ ects the opportunity cost of spending money 
on a particular programme rather than on a standard 
alternative programme.32 The starting age of the cohort was 
22 years. In one-way sensitivity analysis, we paid particular 
attention to addiction treatment enrolment, addiction 
treatment eﬃ  cacy, rate of relapse to injection drug use, and 
PrEP adherence, because there is ample uncertainty about 
their precision and they were shown to have substantial 
eﬀ ects on the value of some strategies. Overall model 
uncertainty was tested in probabilistic sensitivity analysis, 
in which we drew 10 000 random values from speciﬁ ed 
probability distributions for each parameter (beta 
distribution for rates, probabilities, and utilities, and 
gamma distribution for costs).33,34
Role of the funding source
The funder of the study consulted on the study design and 
selection of parameters, provided Connecticut-speciﬁ c cost 
data, and provided feedback on this report. All authors had 
access to the raw data. The corresponding author had full 
access to all of the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Survival was greatest for the strategy combining naloxone 
distribution, PrEP, and linkage to addiction treatment, 
followed by the naloxone distribution plus PrEP strategy, 
the naloxone distribution plus linkage to addiction 
treatment strategy, naloxone distribution alone, and no 
additional intervention (ﬁ gure 1). Survival at 20 years was 
82·8%, 82·4%, 81·1%, 80·6%, and 79·8%, respectively.
The combination of naloxone distribution, PrEP, and 
linkage to addiction treatment prevented the most HIV-
related deaths (21 HIV-related deaths averted in 20 years), 
followed by naloxone distribution plus PrEP (15 HIV-
related deaths averted), and naloxone distribution plus 
linkage to addiction treatment (four HIV-related deaths 
averted; table 1). However, more HIV-related deaths 
occurred with the naloxone distribution strategy 
compared with no additional intervention (two additional 
deaths in 20 years). The greater number of HIV-related 
deaths is explained by the improved likelihood of 
overdose survival with the naloxone distribution strategy 
and continued exposure to HIV infection. Similarly, the 
strategy that combined naloxone distribution, PrEP, and 
linkage to addiction treatment prevented the most 
overdose deaths (149 overdose deaths averted in 20 years, 
a 21% reduction in deaths compared with no additional 
intervention), followed by naloxone distribution plus 
PrEP (127 overdose deaths averted, an 18% reduction 
compared with no additional intervention), naloxone 
distri bution plus linkage to addiction treatment 
(69 overdose deaths averted, a 10% reduction compared 
with no additional intervention), and naloxone distri-
bution alone (44 overdose deaths averted, 6% reduction 
compared with no additional intervention).
In the base case analysis, compared with no additional 
intervention, the naloxone distribution strategy yielded 
an ICER of $323 per QALY. Naloxone distribution plus 
linkage to addiction treatment was cost saving compared 
with no additional intervention (greater gain in QALYs 
and less costly). 
When all strategies were simultaneously considered 
(table 2), naloxone distribution plus linkage to addiction 
treatment was cost saving compared with no additional 
intervention, naloxone distribution alone, and naloxone 
distribution plus PrEP. Thus, the latter three interventions 
were judged to be dominated strategies (more costly and 
less eﬀ ective compared with an alternative) and removed 
from consideration. The combination of naloxone 
distribution, PrEP, and linkage to addiction treatment 
produced better health outcomes, but was also more 
costly compared with the naloxone distribution plus 
linkage to addiction treatment strategy and yielded an 
ICER of $95 337. Therefore, at the societal willingness-to-
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Figure 1: Lifetime survival probability by strategy
PrEP=pre-exposure prophylaxis. 
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pay threshold of $100 000 per QALY, the preferred 
strategy was the combination of naloxone distribution, 
PrEP, and linkage to addiction treatment, whereas if 
lower willingness-to-pay (ie, more stringent) thresholds 
were used, the naloxone distribution plus linkage to 
addiction treatment strategy was preferable.
In sensitivity analysis, when the annual probability of 
relapse (return to injection drug use) increased to 18·9% 
(among individuals enrolled in addiction treatment), 
naloxone distribution plus linkage to addiction treatment 
was no longer cost saving compared with naloxone 
distribution alone because of the added cost associated 
with increased HIV infections (table 3), although the 
strategy was still cost-eﬀ ective even at the highest plausible 
value of 85% (ICER $16 792; ﬁ gure 2). When the likelihood 
of discontinuing injection drug use because of treatment 
declined to less than 23·7%, naloxone distribution plus 
linkage to addiction treatment was no longer cost saving, 
but was still cost-eﬀ ective at the lowest plausible value of 
8·6% (ICER $10 293). When the likelihood of entering 
addiction treatment for strategies that included referral to 
addiction treatment was less than 5·5%, the naloxone 
distribution plus linkage to addiction treatment strategy 
remained dominant and QALYs increased (90 716 vs 68 114 
QALYs) while costs decreased ($209 880 493 vs $279 037 947). 
Strategies that included referral to addiction treatment 
became unfavourable when the probability of addiction 
treatment enrolment dropped below the baseline value of 
4%. When the scale of strategy implementation reached 
90% participation, naloxone distribution plus linkage to 
addiction treatment was no longer cost saving compared 
with no additional intervention (threshold 58%) and 
yielded an ICER of $1317.
For several variables, variation raised ICERs for the 
strategy combining naloxone distribution, PrEP, and 
Number of HIV-related 
deaths averted
Number of overdose 
deaths averted
Proportion of overdose 
deaths averted (%)
Individual life 
expectancy (years)
Survival 
probability (%)
5 years
No additional intervention Reference Reference Reference 4·9 95·2%
Naloxone distribution 0·0 14 6·6% 4·9 95·5%
Naloxone distribution plus PrEP 1·0 42 20·2% 4·9 96·0%
Naloxone distribution plus linkage to 
addiction treatment
0·0 16 7·7% 4·9 95·5%
Naloxone distribution plus PrEP and 
linkage to addiction treatment
1·0 44 21·1% 4·9 96·1%
10 years
No additional intervention Reference Reference Reference 9·5 90·1%
Naloxone distribution 0 25 6·5% 9·5 90·5%
Naloxone distribution plus PrEP 5 77 19·7% 9·6 91·6%
Naloxone distribution plus linkage to 
addiction treatment
1 34 8·7% 9·6 90·7%
Naloxone distribution plus PrEP and 
linkage to addiction treatment
6 84 21·6% 9·6 91·7%
20 years
No additional intervention Reference Reference Reference 18·0 79·3%
Naloxone distribution –2 44 6·3% 18·1 80·0%
Naloxone distribution plus PrEP 15 127 18·2% 18·3 81·9%
Naloxone distribution plus linkage to 
addiction treatment
4 69 9·8% 18·1 80·6%
Naloxone distribution plus PrEP and 
linkage to addiction treatment
21 149 21·2% 18·3 82·4%
PrEP=pre-exposure prophylaxis. 
Table 1: Population health outcomes at time horizons of 5, 10, and 20 years
Life expectancy 
(years)
QALY Cost (US$ 2015) ICER (US$)* 
Most eﬃ  cient strategies
Naloxone distribution plus linkage 
to addiction treatment
97 843 68 114 279 037 947 ··
Naloxone distribution plus PrEP 
and linkage to addiction treatment
98 810 68 746 339 304 861 95 337
Dominated strategies removed from consideration
Naloxone distribution plus PrEP 98 693 67 294 335 144 357 ··
No additional intervention 97 145 66 343 281 741 918 ··
Naloxone distribution 97 614 66 660 281 844 303 ··
The most eﬃ  cient strategies are sorted by cost (ascending). Note that the default strategy (no additional intervention) 
is itself strongly dominated. The naloxone distribution plus PrEP strategy yielded greater unadjusted life expectancy 
than the naloxone distribution plus linkage to addiction treatment strategy, but the disutility associated with injection 
drug use adversely aﬀ ected quality of life. ICER=incremental cost-eﬀ ectiveness ratio. PrEP=pre-exposure prophylaxis. 
QALY=quality-adjusted life-year.  *Incremental diﬀ erence in cost divided by the incremental diﬀ erence in QALY. 
Table 2: QALY, cost, and ICER at 20 years
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linkage to addiction treatment above the $100 000 threshold 
(compared with the naloxone distribution plus linkage to 
addiction treatment strategy; ﬁ gure 3 and appendix). The 
combination of naloxone distribution, PrEP, and linkage 
to addiction treatment was higher than the 
$100 000 threshold when the annual likelihood of HIV 
infection while on PrEP was higher than 1·6%, PrEP 
adherence was less than 38·7%, and the cost of PrEP was 
greater than $12 300. Scenarios related to injection drug 
use that pushed the ICER above the threshold included 
when addiction treatment enrolment was greater than 
6·4%, discontinuing injection drug use in the linkage to 
addiction treatment strategy was greater than 46·7%, 
discontinuing injection drug use after an overdose episode 
was greater than 9·5%, relapse to injection drug use was 
less than 40%, HIV incidence without PrEP was less than 
2·1%, disutility associated with active injection drug use in 
individuals who were HIV negative was less than 0·61, 
and disutility associated with discontinued injection drug 
use in individuals who were HIV negative was less than 
0·90. Scenarios related to overdose that raised the ICER 
above the threshold included when the likelihood of 
overdose was less than 7%, the likelihood of paramedic 
dispatch when no kit was used was more than 32·3%, and 
the likelihood of surviving overdose without intervention 
was more than 58%. An annual discount rate of less than 
2·5% also raised the ICER above $100 000.
The results of the probabilistic sensitivity analysis are 
shown in the cost-eﬀ ectiveness acceptability curves 
(appendix) and show the likelihood of a strategy being 
judged as the optimal strategy (ie, yielding the highest 
net beneﬁ t) for a range of willingness-to-pay thresholds. 
The combination of naloxone distribution, PrEP, and 
linkage to addiction treatment was the optimal strategy 
in 37% of iterations using a willingness-to-pay of 
$100 000, followed by naloxone distribution plus linkage 
to addiction treatment, which was the optimal strategy 
34% of the time. The naloxone distribution plus PrEP 
strategy, naloxone distribution alone, and no additional 
intervention were optimal strategies 11%, 10%, and 8% of 
the time, respectively, at that threshold. At lower 
thresholds (<$85 300), naloxone distribution plus linkage 
to addiction treatment maintained the highest probability 
of being the optimal strategy.
Discussion
Our analyses suggest that naloxone distribution through 
syringe service programmes provides good value for 
money compared with no additional intervention. The 
addition of linkage to addiction treatment saves money 
compared with either no additional intervention or 
naloxone distribution alone. Combining PrEP with 
naloxone distribution and linkage to addiction treatment 
resulted in the greatest health gains and was cost-eﬀ ective, 
with an ICER of less than $100 000 per QALY gained.
Deterministic and probabilistic sensitivity analyses 
showed that results pertaining to the cost-saving 
determination of combined naloxone distribution and 
linkage to addiction treatment compared with naloxone 
distribution alone were robust. Only when relapse to 
injection drug use increased to more than 18·9% and 
when the likelihood of discontinuing injection drug use 
declined to less than 23·7% was the combined strategy no 
longer cost saving, although in both cases the combined 
strategy was good value for money even at maximum 
plausible values. Conversely, for the all-inclusive strategy 
(naloxone distribution, linkage to addiction treatment, and 
PrEP), ICERs were more sensitive to variation and several 
scenarios pushed ICERs above $100 000.
The ICER for the naloxone distribution strategy 
compared with the no additional intervention strategy 
was $323 per QALY, which is similar to the ICER of $421 
reported in a recent modelling study that compared 
community naloxone distribution with no intervention.9 
Although we found no modelling studies that assessed 
our combination of interventions, we did identify two 
that assessed the individual components. Zaric and 
colleagues12 compared methadone treatment alone 
versus no intervention and reported ICERs of $11 923 
(US$ 2015) in settings with a low prevalence of HIV and 
$15 850 in settings with a high prevalence of HIV. These 
ICER (US$)
Relapse to injection drug use; annual probability threshold >18·9%
Naloxone distribution ··
Naloxone distribution plus linkage to addiction treatment 33
Naloxone distribution plus PrEP and linkage to addiction treatment 70 492
Discontinuing injection drug use after treatment; annual probability threshold <23·7%
Naloxone distribution ··
Naloxone distribution plus linkage to addiction treatment 45
Naloxone distribution plus PrEP and linkage to addiction treatment 71 933
Entering treatment, baseline without intervention; annual probability threshold <5·5%
Naloxone distribution ··
Naloxone distribution plus PrEP 86 593
Strategy scale or participation; annual probability threshold <58%
No intervention ··
Naloxone distribution plus linkage to addiction treatment 16
Naloxone distribution plus PrEP and linkage to addiction treatment 158 093
ICER=incremental cost-eﬀ ectiveness ratio. PrEP=pre-exposure prophylaxis. 
Table 3: Sensitivity analysis showing scenarios when naloxone distribution plus linkage to addiction 
treatment was no longer cost saving
$16 792 (1·91)(0·034) –$2526
$10 293 (0·09)
Base case ICER $323
ICER (US$)
(0·83) –$2789
Discontinue injection 
drug use, treatment
Relapse
–$10 000 $10 000 $20 000$0
Figure 2: Scenarios when naloxone distribution plus linkage to addiction treatment is no longer cost saving 
compared with naloxone distribution alone
Corresponding rates are in parentheses.
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ICERs diﬀ er from our ﬁ nding that linkage to addiction 
treatment is cost saving. Both our study and the study by 
Zaric and colleagues show the substantial health beneﬁ ts 
gained from addiction treatment as a result of HIV 
infections averted. However, there are fundamental 
diﬀ erences between models; increasing the cost of 
addiction treatment and lowering the cost of HIV care to 
levels approximating those used in the study by Zaric 
and colleagues produced results trending in their 
direction (ie, greater cost and eﬀ ectiveness of the 
naloxone distribution plus linkage to addiction treatment 
strategy compared with no intervention). The discrepancy 
in the costs used might be attributable to actual changes 
in the cost of treatment, because costs used by Zaric and 
colleagues reﬂ ect the cost of treatments in 1996–98, while 
ours reﬂ ect current-day costs.
Bernard and colleagues35 reported an ICER of $253 000 
per QALY for PrEP use in people who inject drugs, which 
is more than double the ICER generated in our analysis 
($95 337). Although there are important methodological 
diﬀ erences between our model and theirs, when we align 
our inputs, particularly increasing enrolment into 
addiction treatment, these diﬀ erences diminish. Other 
previous studies that assessed the value of PrEP in at-risk 
individuals also reported ICERs well above $100 000 per 
QALY, for example as high as $350 353 in men who have 
sex with men.14 Cost-eﬀ ectiveness of PrEP was attained 
when it was targeted at very high-risk individuals, for 
example $48 430 per QALY when annual HIV incidence 
was 2·3% (which is similar to our estimate of 2·6%).13 
Notably, combination interventions including PrEP were 
cost-eﬀ ective even though we assumed that adherence 
would be low (30%) in injection drug users. The 
diﬀ erences between the PrEP models are extensive, thus 
it is diﬃ  cult to comment on whether results diﬀ er 
because of diﬀ erences in model approach, structure, or 
inputs. Yet, across all studies, results were sensitive to 
HIV prevalence, HIV incidence, and the cost of PrEP. In 
all studies, cost-eﬀ ectiveness of PrEP improved when 
HIV incidence or prevalence was high.
Our study has several limitations. The combined 
interventions considered in the analysis have yet to be 
tested and thus the true eﬀ ect of combining strategies is 
unknown. We used estimates for treatment enrolment, 
adherence, and eﬃ  cacy based on studies that tested the 
strategy components independently. We also only analysed 
one model of linkage to addiction treatment (methadone 
via an opioid treatment programme) and recognise that in 
practice people might also independently or in combin-
ation be enrolled in other types of programmes (ie, 
inpatient treatment, oﬃ  ce-based buprenorphine). More-
over, we did not simulate hepatitis C infection or down-
stream societal eﬀ ects such as crime and incarceration, 
which could have aﬀ ected our results. The addition of 
such pathways is likely to lead to more favourable results 
for strategies that include linkage to addiction treatment, 
because they would reduce the number of people who 
inject drugs compared with the other strategies, thereby 
leading to a reduced risk of hepatitis C infection and 
possibly reduced crime and incarceration. Finally, we did 
not consider whether possession of naloxone encourages 
riskier heroin use, although if we assume risker heroin 
use would lead to an increase in the overdose rate, we may 
have captured this eﬀ ect in our sensitivity analysis when 
ICER (US$)
Enter addiction treatment with linkage
Discontinue injection drug use, overdose
Relapse
Paramedics, no naloxone
Discontinue injection drug use, addiction treatment 
HIV incidence, on PrEP, injection drug use
Overdose rate
HIV incidence, no PrEP, injection drug use
PrEP, cost
Discount rate for costs
PrEP adherence
HIV-negative injection drug use, utility
Survive overdose, no naloxone kit, no paramedics
Base case ICER $95 337
$446 550 (0·96)(0·05) $89 611
$179 767 (0·94)
$172 907 (0·47)
(0·79) $74 015
$146 429 (0·28)
(0·78) $95 337
$128 602 (0)
(0·98) $70 577
$122 261 ($14 800)
(0·06) $73 146
$120 793 (0·01)
($8800) $68 413
$119 934 (0·06)
(0·05) $65 257
$113 860 (0·03)
(0·34) $36 550
$108 651 (0·83)
(0·01) $83 872
$108 237 (0·50)
(0·09 $63 342
$104 549 (0·03)
(0·29) $92 762
(1·91) $55 023
$100 944 (0·11)(0·03) $91 553
Figure 3: Scenarios when ICERs for the combination of naloxone distribution, PrEP, and linkage to addiction treatment were more than US$100 000
Corresponding rates are in parentheses. ICER=incremental cost-eﬀ ectiveness ratio. PrEP=pre-exposure prophylaxis. 
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16 Kidorf M, King VL, Peirce J, Kolodner K, Brooner RK. A treatment 
reengagement intervention for syringe exchangers. 
J Subst Abuse Treat 2011; 41: 415–21.
17 Rapp RC, Otto AL, Lane DT, Redko C, McGatha S, Carlson RG. 
Improving linkage with substance abuse treatment using brief case 
management and motivational interviewing. Drug Alcohol Depend 
2008; 94: 172–82.
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management intervention on drug treatment entry among 
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on antiretroviral therapy adherence and viral suppression in 
HIV-infected drug users. J Gen Intern Med 2002; 17: 377–81.
23 Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy 
adherence and viral suppression in HIV-infected drug users: 
comparison of self-report and electronic monitoring. Clin Infect Dis 
2001; 33: 1417–23.
24 Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 
130: 584–90.
25 Boyer EW. Management of opioid analgesic overdose. N Engl J Med 
2012; 367: 146–55.
26 Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics 
of an overdose prevention, response, and naloxone distribution 
program in Pittsburgh and Allegheny County, Pennsylvania. 
J Urban Health 2011; 88: 1020–30.
27 Lankenau SE, Wagner KD, Silva K, et al. Injection drug users 
trained by overdose prevention programs: responses to witnessed 
overdoses. J Community Health 2013; 38: 133–41.
28 Arias E. United States life tables, 2010. Nat Vital Stat Rep 2014; 
63: 1–63.
29 Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical 
cost savings from preventing HIV in the United States. Med Care 
2015; 53: 293–301.
30 Zarkin GA, Dunlap LJ, Wedehase B, Cowell AJ. The eﬀ ect of 
alternative staﬀ  time data collection methods on drug treatment 
service cost estimates. Eval Program Plann 2008; 31: 427–35.
31 Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. 
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Medicine. JAMA 1996; 276: 1253–58.
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economic evaluation. Oxford: Oxford University Press, 2006.
35 Bernard CL, Brandeau ML, Humphreys K, et al. Cost-eﬀ ectiveness 
of HIV preexposure prophylaxis for people who inject drugs in the 
United States. Ann Intern Med 2016; published online April 26. 
DOI:10.7326/M15-2634.
we varied the annual overdose rate to the upper bound of 
0·34. At this higher level, the results did not change.
In future research, we recommend trials that test the 
eﬃ  cacy and feasibility of combined strategies and that 
identify possible alternative modes of delivery. We also 
recommend extending current modelling work to 
include hepatitis C infection, HIV and HCV co-infection, 
and the eﬀ ect and cost of newer direct-acting antivirals to 
treat hepatitis C.
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